source
- Capricor trims 10% of workforce as FDA decision on Duchenne cell therapy approachesCapricor Therapeutics announced it is cutting about 10% of its staff ahead of an upcoming FDA decision on its Duchenne muscular dystrophy cell therapy, deramiocel. The biotech said it had 231 full…
- MDCalc unveils CrossCover to boost clinician confidence in AI chatbot answers while protecting privacyMDCalc, a medical reference website, announced a new tool called CrossCover. CrossCover is designed to check clinicians' queries for privacy issues and evaluate AI chatbot responses for accuracy,…